BNP PARIBAS ASSET MANAGEMENT Holding S.A. Purchases 297,850 Shares of Alphatec Holdings, Inc. (NASDAQ:ATEC)

BNP PARIBAS ASSET MANAGEMENT Holding S.A. grew its position in shares of Alphatec Holdings, Inc. (NASDAQ:ATEC) by 11.3% in the 3rd quarter, HoldingsChannel.com reports. The fund owned 2,928,094 shares of the medical technology company’s stock after buying an additional 297,850 shares during the quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A.’s holdings in Alphatec were worth $16,280,000 at the end of the most recent quarter.

Other institutional investors also recently modified their holdings of the company. Jennison Associates LLC purchased a new position in Alphatec during the 3rd quarter valued at about $686,000. Wrapmanager Inc. increased its stake in shares of Alphatec by 9.5% during the third quarter. Wrapmanager Inc. now owns 38,399 shares of the medical technology company’s stock valued at $213,000 after buying an additional 3,325 shares during the period. Royce & Associates LP raised its holdings in shares of Alphatec by 15.9% during the third quarter. Royce & Associates LP now owns 1,212,286 shares of the medical technology company’s stock valued at $6,740,000 after acquiring an additional 165,954 shares in the last quarter. Zions Bancorporation N.A. lifted its stake in Alphatec by 108.2% in the third quarter. Zions Bancorporation N.A. now owns 173,180 shares of the medical technology company’s stock worth $963,000 after acquiring an additional 89,992 shares during the period. Finally, GSA Capital Partners LLP purchased a new stake in Alphatec in the third quarter worth $431,000. 66.35% of the stock is currently owned by hedge funds and other institutional investors.

Alphatec Price Performance

Shares of NASDAQ ATEC opened at $10.06 on Friday. The firm has a market cap of $1.43 billion, a P/E ratio of -7.86 and a beta of 1.31. Alphatec Holdings, Inc. has a twelve month low of $4.88 and a twelve month high of $17.34. The company has a quick ratio of 1.15, a current ratio of 2.32 and a debt-to-equity ratio of 30.21. The company has a 50 day moving average of $6.71 and a 200 day moving average of $8.27.

Analyst Upgrades and Downgrades

Several research analysts have commented on ATEC shares. Needham & Company LLC restated a “buy” rating and issued a $13.00 price objective on shares of Alphatec in a report on Thursday, October 31st. Morgan Stanley downgraded shares of Alphatec from an “overweight” rating to an “equal weight” rating in a research note on Thursday, August 1st. Lake Street Capital reduced their target price on Alphatec from $32.00 to $18.00 and set a “buy” rating on the stock in a report on Tuesday, September 3rd. Canaccord Genuity Group reissued a “buy” rating and issued a $20.00 target price on shares of Alphatec in a research report on Friday, August 30th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $20.00 price target on shares of Alphatec in a research note on Thursday, October 31st. One investment analyst has rated the stock with a hold rating and eight have given a buy rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $17.11.

About Alphatec

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.